Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of the drug reduced HIV infections by 96 percent. Data from the trial, known as PURPOSE 2, monitored cisgender men, transgender men, transgender women, and gender nonbinary...

View Entire Post